Targeting angiogenesis for the treatment of advanced melanoma

Oncology Reviews 09/2011; 5(3):167-176. DOI: 10.1007/s12156-011-0075-2

ABSTRACT Metastatic melanoma (MM) carries a dismal prognosis, as it is largely resistant to conventional chemotherapy, bio-chemotherapy
and immunotherapy. The search for new effective treatments is an unquestionable priority in MM. A wealth of novel therapies
have been currently tested in oncology and MM represents an attractive model for investigation. The process of angiogenesis
is crucial for the establishment and progression of most solid tumors including melanoma. As the mechanisms of angiogenesis
are being elucidated, strategies against angiogenic targets are among the most innovative in oncology drug development. Multiple
growth factors secreted in melanoma trigger angiogenic responses and a variety of receptors are activated. Many of these function
in synergy with the extracellular matrix, setting in motion downstream pathways. It is unlikely, therefore, that targeting
a single angiogenic axis will be sufficient to achieve tumor control in melanoma, as exemplified by several negative trials
conducted to date. Current anti-angiogenic strategies include those targeting pro-angiogenic ligands (bevacizumab, VEGF-Trap:
aflibercept), kinases associated with cell surface receptors and growth factor pathways (sorafenib, axitinib, erlotinib, imatinib),
matrix metalloproteinases (MMPs), intergrins [batimastat, marimastat, etaracizomab (abegrin)] and potentially mTOR inhibitors
(everolimus). Many of those recently developed compounds targeting key angiogenic pathways are in the final clinical trial
stages. Future approaches to tackling angiogenesis in MM should take into account therapeutic synergism and drug resistance,
by combining novel agents with different mechanisms of action against different angiogenic pathways. In this review, we focus
primarily on current anti-angiogenic strategies in melanoma, with a view to future developments.

KeywordsMelanoma–Angiogenesis–Growth factors–VEGF inhibitors

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is ╬┐ne of the most aggressive forms of skin cancer. Currently available treatments have little overall impact on survival rates of patients with advanced melanoma. Advances in the understanding of the molecular pathways related to tumor growth and metastatic spread have resulted in the development of targeted therapies designed to act on specific genes or molecules of these pathways. Newly introduced agents that target the process of angiogenesis or inhibit antiapoptotic proteins have been investigated in melanoma. Although the use of these agents as monotherapy has yielded disappointing results, their impact on survival when combined with cytotoxic chemotherapy agents is currently under investigation. Larger phase III trials are needed to clarify the optimal clinical benefit that can be expected of this class of agents.
    Clinics in dermatology 05/2013; 31(3):257-63. DOI:10.1016/j.clindermatol.2012.08.018 · 1.93 Impact Factor